

DCAT

TOP
Industry
NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

Patheon
A HEALTHIER WORLD. DELIVERED.

Executive insights. Delivered.

[Learn more](#)

1. [PhRMA Comments on Meeting with President Trump](#)

Pharmaceutical industry executives and representatives from the Pharmaceutical Research and Manufacturers of America (PhRMA) met with US President Donald Trump this week to discuss issues of common interest, including drug pricing, regulatory reform, and drug manufacturing in the US.

[Read More](#)

2. [Teva to Appeal Ruling Invalidating Patents for Top-Selling MS Drug](#)

Teva Pharmaceutical Industries plans to appeal a recent court ruling that invalidated four of its patents for Copaxone (glatiramer acetate injection), a multiple sclerosis drug and a leading product for Teva with 2015 sales of \$4 billion. [Read More](#)

3. [Lilly Terminates \\$570-Million Insulin Partnership](#)

Eli Lilly and Company has terminated its \$570-million collaboration with Adocia, a Lyon, France-headquartered biopharmaceutical company, for the development of Adocia's ultra-rapid insulin, BioChaperone Lispro. [Read More](#)

4. [EMA Advisory Committee Recommends Amgen's Humira Biosimilar](#)

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing approval of two biosimilar candidates from Amgen of AbbVie's Humira (adalimumab), AbbVie's top-selling drug with 2016 global sales of \$16 billion. [Read More](#)

5. [Novo Nordisk Invests \\$143 Million in Diabetes Center](#)

Novo Nordisk is investing Danish kroner 1 billion (\$143 million) over the next 10 years for a new research center on the University of Oxford's campus as part of a collaboration with the UK-based university to develop Type 2 diabetes therapies. [Read More](#)

6. [Biogen Completes Spin-Off of Hemophilia Business Bioverativ](#)

Biogen has completed the spin-off of its global hemophilia business into a new company, Bioverativ, which is focused on hemophilia and other rare blood disorders. [Read More](#)

7. [European Patent Office Decides BMS Cancer-Drug Patent is Invalid](#)

The European Patent Office has upheld a decision that found a patent for Bristol-Myers Squibb's (BMS) anti-cancer drug, Sprycel (dasatinib), to be invalid. Sprycel is a leading drug in BMS's oncology portfolio with \$1.8 billion in 2016 sales. [Read More](#)

8. [Almac Invests in Ireland Facility](#)

In the latest of a series of expansions, Almac Group is making an undisclosed multi-million British pound investment for a new facility in Dundalk, County Louth, Ireland. Almac is also investing £27 million (\$34 million) to expand its Northern Ireland global headquarters and North American headquarters. [Read More](#)

9. [Sanofi in \\$61.5-Million Class-Action Settlement for Vaccine](#)

Sanofi Pasteur, the vaccines unit of Sanofi, has agreed to pay \$61.5 million to settle a class-action lawsuit involving its meningococcal vaccine, Menactra, a key product in its vaccine franchise. [Read More](#)

10. [Patheon Completes Acquisition of Roche's API Manufacturing Facility](#)

Patheon has completed the acquisition of Roche's active pharmaceutical ingredient (API) manufacturing facility in Florence, South Carolina. The site adds a 300,000 square-foot facility with capacity for development and manufacturing services. [Read More](#)

[DCAT Week '17: Pharmaceutical Industry Outlook](#)

So how will the pharmaceutical industry fare in 2017 and beyond? A DCAT Week '17 education program, [Pharma Industry Outlook: Market Overview and Executive Insights](#), provides the latest market data and executive insight on the issues impacting drug development and commercialization. [Read More](#)

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org